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Linking Drug-Eluting Stent
Kinetics and Clinical Outcomes
Insights From Optical Coherence Tomography*
Brigitta C. Brott, MD
Birmingham, Alabama
Drug-eluting stent release kinetics matter. This is demon-
strated by the study of Guagliumi et al. (1) in this issue of
JACC: Cardiovascular Interventions, which provides a descrip-
tion of the vascular responses to the next generation Resolute
zotarolimus-eluting (sustained release) stent (Medtronic, Min-
neapolis, Minnesota). Vascular responses to this Resolute stent
are compared with those of the original Endeavor stent
(Medtronic), which delivers a more rapid release of zotarolimus.
See page 778
Optical coherence tomography (OCT) imaging demon-
strates that the Resolute sustained zotarolimus release stent
yields less neointimal proliferation but more uncovered stent
struts compared with the stent with faster release kinetics.
These OCT findings provide an explanation for the results
of the RESOLUTE All-Comers trial. This paper demon-
strates that OCT can yield early clues to the efficacy and
safety of new drug-eluting stent platforms by providing both
endothelialization and neointimal proliferation data.
Zotarolimus-Eluting Stent Technology
The original Endeavor stent uses a cobalt-chromium platform,
and releases zotarolimus rapidly (ZES-FR, zotarolimus-
eluting stent faster-release kinetics) from a phosphorylcholine
coating. Less than 50% of the zotarolimus remains on the stent
at 24 h, and6% at 7 days (2). The ZES-FR stent has a lower
estenosis rate compared with bare-metal stents (BMS) (3),
nd provides greater neointimal coverage compared with
irolimus-eluting stents (SES) and paclitaxel-eluting stents
PES) (4,5). However, at 6-month follow-up, the Endeavor
tent is less effective at preventing restenosis than SES and
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LLC.ES, although the restenosis difference with PES is less
vident at longer-term follow-up (6–9).
The Resolute stent is the next generation of the Medtronic
otarolimus-eluting stent (ZES-SR, zotarolimus-eluting
tent sustained-release kinetics). It is composed of the same
obalt-chromium stent platform coated with a durable
olymer designed for more prolonged drug release. The
iolinx polymer is comprised of 3 components: a hydro-
hobic portion to serve as a reservoir for zotarolimus, a
ydrophilic polymer to enhance vascular compatibility, and
n additional hydrophilic polymer to provide the initial
urst release and enhance biocompatibility (10,11). This
polymer combination provides an initial burst release of
drug followed by sustained release, with half of the drug
eluted in the first week and continued drug release beyond
4 weeks (10). In animal models, this combination demon-
strates less late lumen loss but similar biocompatibility to
BMS and ZES-FR stents (2,11).
The RESOLUTE first-in-man registry (12) and the
RESOLUTE All-Comers trial (13) provide safety and
efficacy data for this newer zotarolimus-eluting stent. The
RESOLUTE All-Comers trial randomized 2,292 patients
to either ZES-SR or everolimus-eluting stents (EES).
Sixty-six percent of the patients had at least 1 off-label
criterion for stent placement (13). At 12 months, the
Resolute ZES stent was not inferior to EES, with no
difference in the primary endpoint of target lesion failure.
There was an in-stent late lumen loss for ZES-SR of 0.27
.43 mm versus 0.19  0.40 mm in the EES group (p 
.08). Of note, the ZES-SR group had a higher rate of
efinite and probable stent thrombosis (1.6%) than the EES
roup (0.7%, p  0.05) (13), but this did not translate into
significant difference in death or myocardial infarction at
2 months. The RESOLUTE All-Comers trial, therefore,
emonstrated that the ZES-SR stent was comparable to
ES in safety and effectiveness (13).
eointimal Strut Coverage and
verlapping Stents
Stent thrombosis and the differences between drug-eluting
stent platforms remains a significant clinical concern. Hu-
man autopsy studies reveal that incomplete healing as
evidenced by uncovered stent struts is the most powerful
histological predictor of late stent thrombosis (14). In
particular, the odds ratio for the presence of thrombus in a
stent is 9.0 (95% confidence interval: 3.5 to 22) for lesions
having a ratio of more than 30% uncovered to total struts
per section (14). Drug-eluting stents elicit differing vascular
healing responses, particularly involving rates of endotheli-
alization (4). In animal studies, these differences between
stent types are especially pronounced in regions of overlap,
with a range of delayed healing, fibrin deposition, and
inflammation (15).
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787The ODESSA (Optical coherence tomography for DES
SAfety) trial sought to evaluate healing responses in patients
receiving overlapping drug-eluting stents (16,17). This trial
randomized 77 patients to overlapping SES, PES, ZES-
FR, or BMS. Angiography, intravascular ultrasound, and
OCT were performed. OCT imaging at 6-month follow-up
demonstrated significant differences in the degree of stent
coverage and strut malapposition between stent types, al-
though there was no significant difference between the
regions of overlap versus nonoverlap. SES and PES had
higher rates of uncovered or malapposed struts compared
with ZES-FR and BMS. In particular, ZES-FR demon-
strated near complete stent strut coverage, whereas SES had
8.1  11.2% uncovered/malapposed struts, and PES had
4.05  10.3% (SES and PES in comparison with ZES-FR
and BMS, p  0.001).
The Current Study
The current paper by Guagliumi et al. (1) describes the
OCT, angiographic, and intravascular ultrasound findings
of 21 patients who received overlapping ZES-SR. These
patients were compared with the 22 historical control
patients from the ODESSA study who received ZES-FR
overlapping stents. OCT assessment at 6 months demon-
strated that ZES-SR had less neointimal thickness, more
uncovered stent struts, and more frames with 30% uncov-
ered struts, when compared with the historical control
evaluation of ZES-FR from the ODESSA study. These
findings are consistent with the expectation that the
ZES-SR would perform similarly to other drug-eluting
stents, as evidenced by similar outcomes to EES in the
RESOLUTE All-Comers trial (13).
An important difference between the ZES-SR group and
the historical control ZES-FR group is the incidence of
diabetes, in that the ZES-FR group had a 50% incidence of
diabetes compared with 14% in the ZES-SR group (p 
0.02). Differences in neointimal thickness and strut coverage
have been found when comparing diabetic and nondiabetic
patients receiving SES (18). The authors address this issue
by comparing strut coverage and neointimal thickness be-
tween diabetes classification for each stent type. This
analysis did not demonstrate differences in response be-
tween diabetic and nondiabetic patients.
This study and the original ODESSA trial focus also on
regions of overlapping stents compared with nonoverlap-
ping segments. The ODESSA study found greater neoin-
timal volume obstruction at regions of overlap for SES,
PES, and ZES-FR (16). Stent overlap was also associated
with more uncovered/malapposed struts for SES and PES,
but not for ZES-FR, which had a low frequency of
uncovered/malapposed struts. Surprisingly, the analysis of
ZES-SR demonstrated no difference in neointimal thick-
ness between overlap versus nonoverlapping regions and noincrease in frequency of uncovered/malapposed struts at the
region of ZES-SR overlap.
This study demonstrates the impact drug-eluting stent
release kinetics can have on neointimal proliferation and
vascular healing. The quest continues for a therapy that
both effectively inhibits restenosis and enhances healing.
OCT can be used to provide early insights into clinical
safety and efficacy as new stents are evaluated.
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